255 related articles for article (PubMed ID: 27372757)
1. LSD1 Histone Demethylase Assays and Inhibition.
Hayward D; Cole PA
Methods Enzymol; 2016; 573():261-78. PubMed ID: 27372757
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors.
Culhane JC; Wang D; Yen PM; Cole PA
J Am Chem Soc; 2010 Mar; 132(9):3164-76. PubMed ID: 20148560
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating α,α-Disubstituted Amino Acids with γ-Turn-Inducing Structures.
Ota Y; Kakizawa T; Itoh Y; Suzuki T
Molecules; 2018 May; 23(5):. PubMed ID: 29734782
[TBL] [Abstract][Full Text] [Related]
4. Identification of SNAIL1 Peptide-Based Irreversible Lysine-Specific Demethylase 1-Selective Inactivators.
Itoh Y; Aihara K; Mellini P; Tojo T; Ota Y; Tsumoto H; Solomon VR; Zhan P; Suzuki M; Ogasawara D; Shigenaga A; Inokuma T; Nakagawa H; Miyata N; Mizukami T; Otaka A; Suzuki T
J Med Chem; 2016 Feb; 59(4):1531-44. PubMed ID: 26700437
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
Ota Y; Miyamura S; Araki M; Itoh Y; Yasuda S; Masuda M; Taniguchi T; Sowa Y; Sakai T; Itami K; Yamaguchi J; Suzuki T
Bioorg Med Chem; 2018 Feb; 26(3):775-785. PubMed ID: 29331452
[TBL] [Abstract][Full Text] [Related]
6. Structure activity relationship and modeling studies of inhibitors of lysine specific demethylase 1.
Zhou C; Wu F; Lu L; Wei L; Pai E; Yao Y; Song Y
PLoS One; 2017; 12(2):e0170301. PubMed ID: 28158205
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological activity of 3-oxoamino-benzenesulfonamides as selective and reversible LSD1 inhibitors.
Xi J; Xu S; Wu L; Ma T; Liu R; Liu YC; Deng D; Gu Y; Zhou J; Lan F; Zha X
Bioorg Chem; 2017 Jun; 72():182-189. PubMed ID: 28460360
[TBL] [Abstract][Full Text] [Related]
8. Drug Design Concepts for LSD1-Selective Inhibitors.
Ota Y; Suzuki T
Chem Rec; 2018 Dec; 18(12):1782-1791. PubMed ID: 30277644
[TBL] [Abstract][Full Text] [Related]
9. Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors.
Kakizawa T; Ota Y; Itoh Y; Suzuki T
Bioorg Med Chem Lett; 2018 Jan; 28(2):167-169. PubMed ID: 29198865
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: a novel class of irreversible inhibitors of histone demethylase KDM1A.
Vianello P; Botrugno OA; Cappa A; Ciossani G; Dessanti P; Mai A; Mattevi A; Meroni G; Minucci S; Thaler F; Tortorici M; Trifiró P; Valente S; Villa M; Varasi M; Mercurio C
Eur J Med Chem; 2014 Oct; 86():352-63. PubMed ID: 25173853
[TBL] [Abstract][Full Text] [Related]
11. Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1 .
Mimasu S; Umezawa N; Sato S; Higuchi T; Umehara T; Yokoyama S
Biochemistry; 2010 Aug; 49(30):6494-503. PubMed ID: 20568732
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
13. [Histone demethylase LSD1 and its biological functions].
Shao GB; Huang XJ; Gong AH; Zhang ZJ; Lu RZ; Sang JR
Yi Chuan; 2010 Apr; 32(4):331-8. PubMed ID: 20423886
[TBL] [Abstract][Full Text] [Related]
14. An Overview on Screening Methods for Lysine Specific Demethylase 1 (LSD1) Inhibitors.
Zheng YC; Chang J; Zhang T; Suo FZ; Chen XB; Liu Y; Zhao B; Yu B; Liu HM
Curr Med Chem; 2017; 24(23):2496-2504. PubMed ID: 28486922
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic analysis of a suicide inactivator of histone demethylase LSD1.
Szewczuk LM; Culhane JC; Yang M; Majumdar A; Yu H; Cole PA
Biochemistry; 2007 Jun; 46(23):6892-902. PubMed ID: 17511474
[TBL] [Abstract][Full Text] [Related]
16. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.
Murray-Stewart T; Woster PM; Casero RA
Amino Acids; 2014 Mar; 46(3):585-94. PubMed ID: 23508577
[TBL] [Abstract][Full Text] [Related]
17. trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1.
Schmidt DM; McCafferty DG
Biochemistry; 2007 Apr; 46(14):4408-16. PubMed ID: 17367163
[TBL] [Abstract][Full Text] [Related]
18. Human histone demethylase LSD1 reads the histone code.
Forneris F; Binda C; Vanoni MA; Battaglioli E; Mattevi A
J Biol Chem; 2005 Dec; 280(50):41360-5. PubMed ID: 16223729
[TBL] [Abstract][Full Text] [Related]
19. New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells.
Hoang N; Zhang X; Zhang C; Vo V; Leng F; Saxena L; Yin F; Lu F; Zheng G; Bhowmik P; Zhang H
Bioorg Med Chem; 2018 May; 26(8):1523-1537. PubMed ID: 29439916
[TBL] [Abstract][Full Text] [Related]
20. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment.
Zheng YC; Yu B; Jiang GZ; Feng XJ; He PX; Chu XY; Zhao W; Liu HM
Curr Top Med Chem; 2016; 16(19):2179-88. PubMed ID: 26881714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
